Description
Roscovitine is an inhibitor of CDKs (1, 2, 5, 7, 9, 12) and L-type Ca2+ channels; it exhibits anti-inflammatory and anticancer activities. Roscovitine resolves neutrophil-driven inflammation. In B-cell lymphoma cells, roscovitine induces cell cycle arrest and apoptosis and inhibits proliferation.
References
Leitch AE, Haslett C, Rossi AG. Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. Br J Pharmacol. 2009 Oct;158(4):1004-16. PMID: 19775281.
Yarotskyy V, Elmslie KS. Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels. Br J Pharmacol. 2007 Oct;152(3):386-95. PMID: 17700718.
Lacrima K, Rinaldi A, Vignati S, et al. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leuk Lymphoma. 2007 Jan;48(1):158-67. PMID: 17325859.